Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 7.2%

Stoke Therapeutics, Inc. (NASDAQ:STOK) shares shot up 7.2% during mid-day trading on Wednesday . The stock traded as high as $16.49 and last traded at $16.46. 277,244 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 932,838 shares. The stock had previously closed at $15.35.

Analyst Upgrades and Downgrades

Several research firms have commented on STOK. Wedbush increased their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, May 7th. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. Canaccord Genuity Group lowered their price objective on Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Monday, May 6th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.57.

Stoke Therapeutics Trading Up 3.3 %

The firm has a market cap of $826.62 million, a price-to-earnings ratio of -6.83 and a beta of 0.82. The company has a fifty day moving average price of $11.40 and a 200-day moving average price of $7.36.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.02. The company had revenue of $2.80 million for the quarter, compared to analysts’ expectations of $3.70 million. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -2.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares of the company’s stock, valued at $423,035. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,622,741 shares of company stock valued at $41,935,115. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently modified their holdings of STOK. Dorsey & Whitney Trust CO LLC purchased a new position in Stoke Therapeutics in the 3rd quarter valued at about $43,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $48,000. Corton Capital Inc. acquired a new stake in shares of Stoke Therapeutics in the third quarter worth approximately $58,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Stoke Therapeutics during the third quarter worth approximately $64,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Stoke Therapeutics in the 1st quarter valued at $141,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.